Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2001
10/11/2001CA2404376A1 O-glucosylated benzamide sglt2 inhibitors and method
10/11/2001CA2404373A1 O-aryl glucoside sglt2 inhibitors and method
10/11/2001CA2404365A1 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
10/11/2001CA2404358A1 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
10/11/2001CA2404350A1 Control of a gene induced by oxidized lipids in human artery wall cells
10/11/2001CA2404300A1 Medical devices suitable for gene therapy regimens
10/11/2001CA2404291A1 Butylnitrone containing compositons for inhibition of cancer development
10/11/2001CA2404040A1 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
10/11/2001CA2403950A1 Treatment of renal disorders
10/11/2001CA2403885A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001CA2403735A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
10/11/2001CA2403612A1 Improved treatment of neovascularization
10/11/2001CA2403242A1 Binding peptides for carcinoembryonic antigen (cea)
10/11/2001CA2403160A1 New combination of a betablocker and a cholesterol-lowering agent
10/11/2001CA2402864A1 D and l etherlipid stereoisomers and liposomes
10/11/2001CA2402586A1 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
10/11/2001CA2402078A1 Divided dose therapies with vascular damaging activity
10/11/2001CA2401854A1 Therapeutic combinations of antihypertensive and antiangiogenic agents
10/11/2001CA2399399A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders
10/11/2001CA2397203A1 Phosphoramidate prodrugs
10/10/2001EP1142910A1 Inhibitors for the formation of soluble human CD23
10/10/2001EP1142909A1 Novel guanosine triphosphate (gtp)-binding protein-coupled receptor protein
10/10/2001EP1142583A1 Antitumor agents
10/10/2001EP1141728A1 Kidney disease detection and treatment
10/10/2001EP1141723A1 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists
10/10/2001EP1141720A1 Detection of preactivated phagocytes
10/10/2001EP1141717A1 Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase
10/10/2001EP1141407A2 Method of identifying a psychotropic agent using differential gene expression
10/10/2001EP1141397A1 Method of sequence identification
10/10/2001EP1141389A2 Reagents and methods useful for detecting diseases of the breast
10/10/2001EP1141386A1 Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
10/10/2001EP1141358A1 ASSAY FOR IDENTIFYING COMPOUNDS WHICH AFFECT STABILITY OF mRNA
10/10/2001EP1141332A1 Human cyclic nucleotide pdes
10/10/2001EP1141325A1 Ikk3 kinase
10/10/2001EP1141288A2 Lymphocytic membrane proteins
10/10/2001EP1141286A1 Cytokine receptor chain
10/10/2001EP1141268A2 $i(A. FUMIGATUS) ACETYL COENZYME-A CARBOXYLASE GENES AND POLYPEPTIDES AND USES THEREOF
10/10/2001EP1141253A1 Crystalline form of activated trap and use thereof for structure-based drug design
10/10/2001EP1141251A1 Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
10/10/2001EP1141246A2 Non-myeloablative tolerogenic treatment
10/10/2001EP1141240A1 Use of cd40 engagement to alter t cell receptor usage
10/10/2001EP1141079A1 Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties
10/10/2001EP1141027A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
10/10/2001EP1141020A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/10/2001EP1141019A2 Substance for producing highly effective anti-tumour medicaments and corresponding method
10/10/2001EP1141017A2 Characterization of the soc/crac calcium channel protein family
10/10/2001EP1141014A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001EP1141003A1 Methods
10/10/2001EP1140999A1 $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
10/10/2001EP1140983A1 Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors
10/10/2001EP1140973A1 Protein-protein interactions in neurodegenerative disorders
10/10/2001EP1140971A1 Antisense modulation of novel anti-apoptotic bcl-2-related proteins
10/10/2001EP1140969A1 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140964A2 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140959A1 Inositol-containing hexasaccharides, their synthesis and their uses
10/10/2001EP1140938A2 High affinity inhibitors for target validation and uses thereof
10/10/2001EP1140937A2 Antiviral nucleoside analogues
10/10/2001EP1140931A1 5ht1 antagonists for antidepressant therapy
10/10/2001EP1140920A1 Piperidines as ccr5 modulators
10/10/2001EP1140906A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
10/10/2001EP1140896A1 Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
10/10/2001EP1140888A1 Optical molecular sensors for cytochrome p450 activity
10/10/2001EP1140876A1 Morpholinone and morpholine derivatives and uses thereof
10/10/2001EP1140837A1 Compounds useful in the treatment of inflammatory diseases
10/10/2001EP1140831A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
10/10/2001EP1140830A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
10/10/2001EP1140291A1 Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor
10/10/2001EP1140290A2 Synergistic tumorcidal response induced by histamine
10/10/2001EP1140289A1 Method for prevention and treatment of cancer and other cell proliferative diseases with ultrasonic energy
10/10/2001EP1140273A2 Device for locally delivering a drug in a body cavity
10/10/2001EP1140240A1 Injectable hyaluronic acid derivative with pharmaceuticals/cells
10/10/2001EP1140208A1 Pharmaceutical compositions comprising immortalised endothelial cells
10/10/2001EP1140198A1 A composition and method for the enhancement of the efficacy of drugs
10/10/2001EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
10/10/2001EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
10/10/2001EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
10/10/2001EP1140191A1 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
10/10/2001EP1140190A1 Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
10/10/2001EP1140189A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
10/10/2001EP1140188A1 Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
10/10/2001EP1140187A1 Combinations for cardiovascular indications
10/10/2001EP1140186A1 Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
10/10/2001EP1140185A1 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
10/10/2001EP1140184A1 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
10/10/2001EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
10/10/2001EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
10/10/2001EP1140181A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
10/10/2001EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
10/10/2001EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia
10/10/2001EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
10/10/2001EP1140174A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines
10/10/2001EP1140173A2 Vascular endothelial cell growth factor antagonists and uses thereof
10/10/2001EP1140171A1 Methods and products for regulating lectin complement pathway associated complement activation
10/10/2001EP1140169A2 Methods and compositions for decreasing allergic reactions to surface allergens
10/10/2001EP1140163A2 Combination of hepatitis b vaccine with antiviral agents
10/10/2001EP1140147A2 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
10/10/2001EP1140141A2 Methods for treating cancer and for mediating chemotaxis of dendritic cells
10/10/2001EP1140136A2 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
10/10/2001EP1140134A1 Agent for treating visual cell function disorder
10/10/2001EP1140132A1 Gonadotropin releasing hormone antagonist
1 ... 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 ... 1151